Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets Greater China JANZ and Emerging Markets. It offers prescription brand drugs generic drugs complex generic drugs biosimilars and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas including noncommunicable and infectious diseases; biosimilars in the areas of oncology immunology endocrinology ophthalmology and dermatology; and APIs for antibacterial central nervous system agents antihistamines/antiasthmatics cardiovascular antivirals antidiabetics antifungals and proton pump inhibitor areas as well as support services such as diagnostic clinics educational seminars and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses injectables complex dosage forms and APIs to retail and pharmacy establishments wholesalers and distributors payers insurers and governments and institutions. The company distributes its products through pharmaceutical wholesalers/distributors pharmaceutical retailers institutional pharmacies mail-order and e-commerce pharmacies and specialty pharmacies. It sells its products under the Lyrica Lipitor Creon Influvac Wixela Inhub EpiPen auto-injector Fraxiparine and Yupelri; Norvasc and Viagra; AMITIZA Lipacreon and Effexor; and Celebrex and ARV names as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics Inc.; Momenta Pharmaceuticals Inc.; Theravance Biopharma Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg Pennsylvania.